| 54.31 -0.37 (-0.68%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 67.28 | 1-year : | 70.44 |
| Resists | First : | 57.6 | Second : | 60.31 |
| Pivot price | 55.89  |
|||
| Supports | First : | 53.22 | Second : | 44.28 |
| MAs | MA(5) : | 54.42 |
MA(20) : | 56.44 |
| MA(100) : | 58.62 |
MA(250) : | 42.32 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 17 |
D(3) : | 12.2 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 72.36 | Low : | 13.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANAB ] has closed above bottom band by 18.6%. Bollinger Bands are 65.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 54.84 - 55.15 | 55.15 - 55.44 |
| Low: | 52.9 - 53.24 | 53.24 - 53.55 |
| Close: | 53.81 - 54.37 | 54.37 - 54.87 |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Tue, 15 Sep 2026
ANAB: Focused on maximizing value from JEMPERLI and imsidolimab royalties, with major milestones ahead - TradingView
Tue, 15 Sep 2026
ANAB: Focused on JEMPERLI and imsidolimab royalties, with major milestones and shareholder returns ahead - TradingView
Mon, 14 Sep 2026
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance
Wed, 09 Sep 2026
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - marketbeat.com
Wed, 09 Sep 2026
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - marketbeat.com
Sun, 06 Sep 2026
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - marketbeat.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 106.3 (%) |
| Shares Short | 5,320 (K) |
| Shares Short P.Month | 5,000 (K) |
| EPS | -1.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | -11.6 % |
| Operating Margin | -135.6 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | -114.6 % |
| Qtrly Rev. Growth | -8 % |
| Gross Profit (p.s.) | 3.49 |
| Sales Per Share | 7.84 |
| EBITDA (p.s.) | 1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -53.25 |
| PEG Ratio | 0 |
| Price to Book value | 123.43 |
| Price to Sales | 6.91 |
| Price to Cash Flow | 358.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|